The control of Leishmania infection relies primarily on chemotherapy till date. Resistance to
pentavalent antimonials, which have been the recommended drugs to treat cutaneous and …

Leishmaniasis affects over 150 million people all over the world, especially in subtropical
regions. Currently used antileishmanial synthesized drugs are associated with some …

Algae have been used since ancient times as food, fodder, fertilizer and as source of
medicine. Nowadays seaweeds represent an unlimited source of the raw materials used in …

Leishmaniasis is a tropical disease threatening 350 million people from endemic regions.
The available drugs for treatment are inadequate, with limitations such as serious side …

The use of indigenous or remote popular knowledge to identify new drugs against diseases
or infections is a well-known approach in medicine. The inhabitants of coastal regions are …

Although there have been significant advances in the treatment of visceral leishmaniasis
(VL) and several novel compounds are currently in pre-clinical and clinical development for …

The current in vivo models for the utility and discovery of new potential anti-leishmanial
drugs targeting Cutaneous Leishmaniasis (CL) differ vastly in their immunological …

Parasitic protozoa are among the most important pathogens worldwide. Diseases such as
malaria, leishmaniasis, amoebiasis, giardiasis, trichomoniasis, and trypanosomiasis affect …

Development of new therapeutic approaches for leishmaniasis treatment requires new high
throughput screening methodologies for the antileishmanial activity of the new compounds …

Background Visceral leishmaniasis (VL) is hypoendemic in the Mediterranean region, where
it is caused by the protozoan Leishmania infantum. An effective vaccine for humans is not …